Data Jin10 July 28, WuXi AppTec announced that the company expects its sustainable operating revenue to return to double-digit growth by 2025, with an updated growth rate from 10-15% to 13-17%. The company estimates total annual revenue will rise from 41.5-43 billion RMB to 42.5-43.5 billion RMB. The company will focus on its core CRDMO business and continue to enhance operational efficiency. During the reporting period, the chemical business achieved a gross profit of 799,844.71 thousand RMB, with a gross profit margin increasing by 5.5% compared to last year, primarily due to ongoing production process optimization and increased capacity efficiency resulting from the growth of late-stage clinical projects and commercialization. The testing business achieved a gross profit of 66,439.04 thousand RMB, with a gross profit margin decreasing by 12.1% compared to last year, mainly influenced by market price factors. The biology business achieved a gross profit of 43,859.63 thousand RMB, with a gross profit margin decreasing by 1.0% compared to last year.